Randomized, Double-Blind Trial of Triple Therapy With Saxagliptin Add-on to Dapagliflozin Plus Metformin in Patients With Type 2 Diabetes

201585 citationsJournal Articlebronze Open Access

Authors

S. Matthäei · Diabetes-Zentrum Quakenbrück

Doina Catrinoiu · Constanta Maritime University

Aleksander Celiñski · Centrum Badań Jakości

Ella Ekholm · AstraZeneca (Sweden)

W. James Cook · AstraZeneca (Japan)

Boaz Hirshberg

Hungta Chen · AstraZeneca (Japan)

Abstract

Triple therapy with the addition of saxagliptin to dapagliflozin plus metformin was well tolerated and produced significant improvements in HbA1c in patients with type 2 diabetes inadequately controlled with dapagliflozin plus metformin.

Topics & Keywords

Diabetes Treatment and Management Diabetes Management and Research Metabolism, Diabetes, and Cancer

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Diabetes Care

Volume 38, Issue 11, pp. 2018-2024

DOI: 10.2337/dc15-0811

Field-Weighted Citation Impact: 9.16